Prophylaxis of Recurrent Hepatitis B in Chinese Patients After Liver Transplantation Using Lamivudine Combined With Hepatitis B Immune Globulin According to the Titer of Antibody to Hepatitis B Surface Antigen

Transplantation Proceedings

Volumn 39, Issue 5, 2007, Pages 1533-1536

  Jiao, Z Y ^a   Jiao, Z ^a  

^a West China Liver Transplantation Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ADULT; ANTIBODY TITER; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTANT;

ADULT; CHINA; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 34250181236     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.03.062     Document Type: Article

References (22)

1. Nair S., Perrillo R.P., et al. Prevention and control of hepatitis B in China. In: Boyer T.D. (Ed). Hepatology. 4th ed. (2003), Saunders, Philadelphia 959
2. Sun Z.T., Ming L.H., Zhu X., et al. Prevention and control of hepatitis B in China. J Medi Virol 67 (2002) 447
3. Zheng S.S., Chen Y.M., Liang T.B., et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transplant 12 (2006) 253
4. Wang Z.X., Fu Z.R., Ding G.S., et al. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Transplant Proc 36 (2004) 2315
5. Samuel D., Muller R., Graeme A., et al. investigators of The European Concerted Action on Viral Hepatitis Study: Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993) 1842
6. Sawyer R.G., McGory R.W., Gaffey M.J., et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 227 (1998) 841
7. McGory R.W., Ishitani M.B., Oliveira W.M., Stevenson W.C., McCullough C.S., Dickson R.C., et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 61 (1996) 1358-1364
8. Terrault N.A., Zhou S., Combs C., et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24 (1996) 1327
9. Terrault N.A., Zhou S., McCory R.W., et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 28 (1998) 555
10. Ghany M.G., Ayola B., Villamil F.G., et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27 (1998) 213
11. Neff G.W., O'Brien C.B., Nery J., et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transplant 10 (2004) 1372
12. Grellier L., Mutimer D., Ahmed M., et al. Lamivudine prophylaxis against recurrence in liver transplantation for hepatitis B cirrhosis. Lancet 348 (1996) 1212
13. Perrillo R.P., Wright T., Rakela J., et al. and The Lamivudine North American Transplant Group: A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33 (2001) 424
14. Lo C.M., Cheung S.T., Lai C.L., et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 233 (2001) 276
15. Yao F.Y., Osorio R.W., Roberts J.P., et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after Liver transplantation. Liver Transplant Surg 5 (1999) 491
16. Yoshida E.M., Erb S.R., Partovi N., et al. Liver transplantation for chronic hepatitis B iInfection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transplant Surg 5 (1999) 520
17. Angus P.W., McCaughan G.W., and Gane E.J. the Australasian Liver Transplant Study Group: Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transplant 6 (2000) 429
18. Han S.H., Martin P., Edelstein M., et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transplant 9 (2003) 182
19. Buti M., Mas A., Prieto M., et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 38 (2003) 811
20. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 334 (1996) 693
21. Angus P.W., McCaughan G.W., Gane E.J., et al. the Australasian Liver Transplant Study Group: Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transplant 6 (2000) 429
22. Marzano A., Gaia S., Ghisetti V., et al. Viral load at the time of liver transplantation and risk of hepatitis b virus recurrence. Liver Transplant 11 (2005) 402